SAN DIEGO, February 26, 2021 — Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing. Other…
SAN DIEGO, January 5, 2021 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer. Dr. Aslan brings a twenty-year track record as an executive and investor in the…
AB-101 is an optimized universal NK cell therapy candidate designed for clinical use with tumor-targeted therapeutics First clinical program applying Artiva’s proprietary large-scale NK-cell manufacturing process for off-the-shelf cellular therapies SAN DIEGO, December 7, 2020 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to…
Funds will be used to establish clinical proof of concept for Artiva’s CAR-NK and universal NK cell therapies Artiva has exclusive access to a proprietary large-scale NK cell manufacturing platform and infrastructure First clinical study planned for later this year followed by two additional clinical programs SAN DIEGO, June 26, 2020 – Artiva Biotherapeutics, Inc.,…